Background: Ursodeoxycholic acid (UDCA) might prevent progression of cystic fibrosis liver disease, but objective parameters for its effect are lacking.
Methods: We used liver stiffness measurements to evaluate the effect of Ursodeoxycholic acid.
Results: Paired measurements of liver stiffness were done in 73 patients without UDCA and in 32 patients with UDCA. In the latter group, 6 patients had cirrhosis; in 15 patients, UDCA was started based on Colombo criteria, and in 11 patients for other reasons. In patients without UDCA, liver stiffness increased: 0.19 (-0.03 to 0.59)kPa/year. Liver stiffness also increased in patients with cirrhosis: 4.6 (0.67-12.4)kPa/year. In patients who had UDCA based on Colombo criteria, a decrease of liver stiffness was observed: 0.70 (-1.6 to 0.55)kPa/year (P=0.01). In patients on UDCA for other reasons, liver stiffness increased: 0.23 (-0.20 to 0.51)kPa/year.
Conclusion: UDCA reduced liver stiffness in patients with well-defined, mild liver disease.
Keywords: Cystic fibrosis liver disease; Fibroscan; Liver stiffness measurement; Ursodeoxycholic acid.
Copyright Â© 2016 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.